# Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects

> **NCT01979380** · PHASE1 · COMPLETED · sponsor: **Kwang Dong Pharmaceutical co., ltd.** · enrollment: 40 (actual)

## Conditions studied

- Drug Toxicity

## Interventions

- **DRUG:** KD101
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01979380
- **Lead sponsor:** Kwang Dong Pharmaceutical co., ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01979380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01979380, "Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01979380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*